Graves disease therapeutic pipeline analysis is expected to increase owing to the high prevalence of the disease. Growing number of cases for hyperthyroidism is a major factor driving the pipeline analysis for Graves disease . In addition, increasing awareness regarding health issues among people is another major factor contributing towards the pipeline for Graves disease. According to American Thyroid Association, the prevalence of Graves disease has increased with increasing hyperthyroidism patients.
Graves disease is the result of hyperthyroidism, which basically means overproduction of thyroid gland. Hyperthyroidism cause majority of symptoms of Graves disease and it can also be associated with eyes inflammation, swelling of the tissues around the eyes and eyes bulging known as Graves ophthalmopathy. The most common symptoms of Graves disease include eye disease and skin disease. Eye disease includes redness of eyes and irritation of the eyes while skin disease includes pretibial myxedema in which a reddish lump is formed in front of the shins. The other symptoms of Graves disease are weight loss, anxiety, erectile dysfunction, change in menstrual cycles, irregular heartbeat and bulging eyes. Graves disease is an autoimmune disease in which antibodies bind to thyroid cells which results in overproduction of thyroid hormones. This results in hyperthyroidism. Graves disease is diagnosed by clinical observation and confirmed by laboratory testing which includes measuring thyroid hormone (thyroxine, or T4, and triiodothyronine, or T3) and thyroid-stimulating hormone (TSH) in patient’s blood. Also family history with thyroid or autoimmune diseases is analyzed. Some of the risk factors of Graves disease include age, family history, smoking, pregnancy and autoimmune disorders. Treatment includes anti-thyroid medications, beta blockers and surgery. It is treated using antithyroid drugs including methimazole [Tapazole] and surgery in severe cases.
Apitope International NV, is introducing a compound named, ATX-GD-59. The compound is in Phase I clinical stage of development, and is being tested for its safety and efficacy in a 12-week trial. ATX-GD-59 is an immunomodulator and is being developed to be administered by intradermal injection route. Novartis Pharmaceuticals, is also testing on safety and efficacy of compound - CFZ533, which is in Phase II stage of development. CFZ533 is a CD40 antigen inhibitor and is being developed to be administered by intravenous route. AV7 Limited, is in the process of developing a compound K1-70 and is being tested for its safety and efficacy for patients diagnosed with Graves disease. K1-70 blocks thyroid stimulating autoantibodies to prevent the overproduction of thyroid. It is being developed to be administered by intramuscular route. Neothetics, Inc., is developing a compound by the name, LIPO-202 which is under clinical development for the treatment of symptomatic exophthalmos associated with Graves disease. It is also known as Salmeterol xinafoate which is being developed to be administered by parenteral route.
Some of the key companies having a pipeline of Graves disease therapeutics include AV7 Limited, Apitope International NV, Neothetics, Inc., Nova Therapeutics LLC, Novartis AG, Omeros Corp. and Rodos BioTarget GmbH.